Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Phthisis Diagnostics Launches New Product Line

Published: Monday, October 01, 2012
Last Updated: Monday, October 01, 2012
Bookmark and Share
G-Sphere® Molecular Standards provides flexible quality control for labs.

Phthisis Diagnostics has just rolled out its new molecular standards product line, the G-Sphere® Molecular Standards.

The new line quickly follows the introduction of the company’s second product in its Simply Molecular® line of enzyme-based extraction kits for rapid sample preparation prior to PCR applications in laboratories.

Phthisis Diagnostics, based in Charlottesville, VA, is a rapidly growing biotechnology company developing a range of innovative molecular diagnostics technologies.

The G-Sphere® Molecular Standards are synthetic genes that provide safe, stable, consistent, and abundant controls for virtually any organism and any molecular assay.

Molecular diagnostic laboratories face difficulties in obtaining consistent and reliable controls to monitor the performance of molecular assays and instruments.

This new Phthisis product line, the only one currently offering such standards for parasites, is an innovative solution to improve and simplify quality control procedures.

The Company has expanded its staff to allow special focus on the development of the new line. Elizabeth Nelson is a Research Technician designated as the Project Lead for the G-Sphere® Molecular Standards.

This custom product is supplied as 100 reaction vials that come with dilution buffer and instructions for use. In addition to custom orders, a growing list of G-Sphere® Molecular Standards have been developed for various parasites, including Cryptosporidium, Giardia, Entamoeba, Plasmodium, Microsporidia, and other analytes of particular interest to public health laboratories.

“This new product provides much needed quality control standards to molecular laboratories,” explains Crystal Icenhour, PhD, President and Chief Science Officer at Phthisis Diagnostics.

Icenhour continued, “We have developed a consensus approach to creating molecular standards, giving the users greater flexibility. We are excited to introduce this product line because it will enable molecular laboratories to better control diagnostic assays. In addition to being a stand-alone product, these molecular standards will be used as positive controls for our diagnostic product line.”

Phthisis Diagnostics will be presenting its new product line for the first time at the 2012 Association for Molecular Pathology (AMP) Annual Meeting in Long Beach, CA, in October.

Interested laboratories are encouraged to stop by Phthisis’ Booth # 332 at this meeting to learn more about G-Sphere® Molecular Standards.

Phthisis Diagnostics products are developed and manufactured in the USA to ISO 13485 standards in a QSR and cGMP compliant facility and are designated as general purpose reagents.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Phthisis Diagnostics Announces Second Round of Funding
With their first product already in the international marketplace and a second just launched, Phthisis Diagnostics has announced a successful second round of angel funding.
Thursday, July 12, 2012
Phthisis Diagnostics Announces First International Distribution Agreement
Simple and cost-efficient molecular products make their way into Latin America.
Friday, May 25, 2012
Phthisis Diagnostics Welcomes New Sales Director and Controller
Appointment of Betty Polk and Robert Owen to Company’s management team.
Monday, May 14, 2012
Scientific News
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
NIH Sequences Genome of a Fungus
Researchers at the Institute have sequenced genome of human, mouse and rat Pneumocystis that cause life-threatening Pneumonia in immunosuppressed hosts.
Antibiotic Resistance Mechanism Continues to Spread
A recently discovered genetic mechanism allowing bacteria to develop and transfer resistance to colistin, one of the last-resort antibiotics, has been present in many countries across the world for more than a decade, according to late-breaking data presented at ECCMID.
Promising New Method Inhibits TB-Causing Bacteria
Researchers at UQ and UC San Francisco have found a new way to inhibit the growth of the bacterium that causes tuberculosis.
Liquid Biopsy for NSCLC
'Liquid biopsy' blood test accurately detects key genetic mutations in most common form of lung cancer, study finds.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!